ES2761406T3 - Protección transitoria de células normales durante una quimioterapia - Google Patents
Protección transitoria de células normales durante una quimioterapia Download PDFInfo
- Publication number
- ES2761406T3 ES2761406T3 ES14762438T ES14762438T ES2761406T3 ES 2761406 T3 ES2761406 T3 ES 2761406T3 ES 14762438 T ES14762438 T ES 14762438T ES 14762438 T ES14762438 T ES 14762438T ES 2761406 T3 ES2761406 T3 ES 2761406T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- days
- day
- cells
- cdk4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(**1)=CC=C1Nc1nc([n](C2(CCCC2)N(*)C2=O)c2c2)c2cn1 Chemical compound *C(**1)=CC=C1Nc1nc([n](C2(CCCC2)N(*)C2=O)c2c2)c2cn1 0.000 description 11
- ZJUDNFSNXBZPTL-UHFFFAOYSA-N CC(C)(C)OC(NCC(C)(C)Nc1nc(Cl)ncc1Br)=O Chemical compound CC(C)(C)OC(NCC(C)(C)Nc1nc(Cl)ncc1Br)=O ZJUDNFSNXBZPTL-UHFFFAOYSA-N 0.000 description 1
- CWMVKGPCVGAQJM-SNVBAGLBSA-N CC(C)(C)[C@@H](CN1C)[n]2c3nc(Cl)ncc3cc2C1=O Chemical compound CC(C)(C)[C@@H](CN1C)[n]2c3nc(Cl)ncc3cc2C1=O CWMVKGPCVGAQJM-SNVBAGLBSA-N 0.000 description 1
- NYYTUGICDWNNQC-UHFFFAOYSA-N CC(C)C(CNC(OC(C)(C)C)=O)Nc1nc(Cl)ncc1Br Chemical compound CC(C)C(CNC(OC(C)(C)C)=O)Nc1nc(Cl)ncc1Br NYYTUGICDWNNQC-UHFFFAOYSA-N 0.000 description 1
- QDPTXMGIRNUPAQ-GZTJUZNOSA-N CC(C)CC(Cc1nc(Nc(cc2)ncc2N2CCNCC2)ncc1/C=C1\C)CNC1=O Chemical compound CC(C)CC(Cc1nc(Nc(cc2)ncc2N2CCNCC2)ncc1/C=C1\C)CNC1=O QDPTXMGIRNUPAQ-GZTJUZNOSA-N 0.000 description 1
- CDCCIDIMKJJXEQ-INIZCTEOSA-N CC(C)C[C@@H](CNC(OC(C)(C)C)=O)NC(OCc1ccccc1)=O Chemical compound CC(C)C[C@@H](CNC(OC(C)(C)C)=O)NC(OCc1ccccc1)=O CDCCIDIMKJJXEQ-INIZCTEOSA-N 0.000 description 1
- JHHZRXVNAVDUGE-OAHLLOKOSA-N CC(C)[C@@H](CNC(OC(C)(C)C)=O)NC(OCc1ccccc1)=O Chemical compound CC(C)[C@@H](CNC(OC(C)(C)C)=O)NC(OCc1ccccc1)=O JHHZRXVNAVDUGE-OAHLLOKOSA-N 0.000 description 1
- GMFIOFITIFIYMM-MRVPVSSYSA-N CC(C)[C@@H](C[n]1c2nc(Cl)ncc2cc11)NC1=O Chemical compound CC(C)[C@@H](C[n]1c2nc(Cl)ncc2cc11)NC1=O GMFIOFITIFIYMM-MRVPVSSYSA-N 0.000 description 1
- LWYDNIYUJPPEEG-QRIPLOBPSA-N CC(C)[C@@H](C[n]1c2nc(Nc(cc3)ncc3N3CCNCC3)ncc2cc11)NC1O Chemical compound CC(C)[C@@H](C[n]1c2nc(Nc(cc3)ncc3N3CCNCC3)ncc2cc11)NC1O LWYDNIYUJPPEEG-QRIPLOBPSA-N 0.000 description 1
- ZJVFYVIGAHVING-LBXVMSDZSA-N CCC(C)[C@@H](CC1CC)[n]2c3nc(Nc(cc4)ncc4N4CCNCC4)ncc3cc2C1=O Chemical compound CCC(C)[C@@H](CC1CC)[n]2c3nc(Nc(cc4)ncc4N4CCNCC4)ncc3cc2C1=O ZJVFYVIGAHVING-LBXVMSDZSA-N 0.000 description 1
- ABFYPQJZBKJZOQ-BZSJEYESSA-N CCC(C)[C@@H](CNC(OC(C)(C)C)=O)NC(OCc1ccccc1)=O Chemical compound CCC(C)[C@@H](CNC(OC(C)(C)C)=O)NC(OCc1ccccc1)=O ABFYPQJZBKJZOQ-BZSJEYESSA-N 0.000 description 1
- UKZMHOCVJFIROD-HCCKASOXSA-N CCC(C)[C@@H](CNC(OC(C)(C)C)=O)Nc1nc(Cl)ncc1Br Chemical compound CCC(C)[C@@H](CNC(OC(C)(C)C)=O)Nc1nc(Cl)ncc1Br UKZMHOCVJFIROD-HCCKASOXSA-N 0.000 description 1
- NIBVMIBRJSODHF-HOTGVXAUSA-N CCOC(C#Cc(c(N[C@@H](CCC1)[C@H]1NC(OC(C)(C)C)=O)n1)cnc1Cl)OCC Chemical compound CCOC(C#Cc(c(N[C@@H](CCC1)[C@H]1NC(OC(C)(C)C)=O)n1)cnc1Cl)OCC NIBVMIBRJSODHF-HOTGVXAUSA-N 0.000 description 1
- PDGKHKMBHVFCMG-UHFFFAOYSA-N CN(CC1)CCN1c(cc1)cnc1Nc1ncc(cc2[n]3C4(CCCCC4)CNC2=O)c3n1 Chemical compound CN(CC1)CCN1c(cc1)cnc1Nc1ncc(cc2[n]3C4(CCCCC4)CNC2=O)c3n1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 1
- INASTCGMVRITIL-UHFFFAOYSA-N Nc(cc1)ncc1N1CCSCC1 Chemical compound Nc(cc1)ncc1N1CCSCC1 INASTCGMVRITIL-UHFFFAOYSA-N 0.000 description 1
- OPWKPWLWUXLMKB-UHFFFAOYSA-N [O-][N+](c(cc1)ncc1N(CC1)CCC1N1CCOCC1)=O Chemical compound [O-][N+](c(cc1)ncc1N(CC1)CCC1N1CCOCC1)=O OPWKPWLWUXLMKB-UHFFFAOYSA-N 0.000 description 1
- OJCWRUDJYGWJLU-UHFFFAOYSA-N [O-][N+](c(cc1)ncc1N1CCSCC1)=O Chemical compound [O-][N+](c(cc1)ncc1N1CCSCC1)=O OJCWRUDJYGWJLU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798772P | 2013-03-15 | 2013-03-15 | |
| US201361861374P | 2013-08-01 | 2013-08-01 | |
| US201361911354P | 2013-12-03 | 2013-12-03 | |
| US201461949786P | 2014-03-07 | 2014-03-07 | |
| PCT/US2014/028685 WO2014144326A1 (en) | 2013-03-15 | 2014-03-14 | Transient protection of normal cells during chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2761406T3 true ES2761406T3 (es) | 2020-05-19 |
Family
ID=51527871
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14762438T Active ES2761406T3 (es) | 2013-03-15 | 2014-03-14 | Protección transitoria de células normales durante una quimioterapia |
| ES14765105T Active ES3032492T3 (en) | 2013-03-15 | 2014-03-14 | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14765105T Active ES3032492T3 (en) | 2013-03-15 | 2014-03-14 | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
Country Status (18)
| Country | Link |
|---|---|
| US (15) | US9527857B2 (enExample) |
| EP (4) | EP2968290B1 (enExample) |
| JP (9) | JP6337083B2 (enExample) |
| CN (4) | CN108434149B (enExample) |
| CA (2) | CA2906166C (enExample) |
| CY (1) | CY1122434T1 (enExample) |
| DK (1) | DK2968290T3 (enExample) |
| ES (2) | ES2761406T3 (enExample) |
| HR (1) | HRP20192168T1 (enExample) |
| HU (1) | HUE046653T2 (enExample) |
| LT (1) | LT2968290T (enExample) |
| ME (1) | ME03557B (enExample) |
| PL (1) | PL2968290T3 (enExample) |
| PT (1) | PT2968290T (enExample) |
| RS (1) | RS59790B1 (enExample) |
| SI (1) | SI2968290T1 (enExample) |
| SM (1) | SMT201900681T1 (enExample) |
| WO (2) | WO2014144847A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| US8691830B2 (en) * | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| WO2013148748A1 (en) | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
| MY175254A (en) | 2012-04-26 | 2020-06-17 | G1 Therapeutics Inc | Synthesis of lactams |
| US9527857B2 (en) | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| US20140271460A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly Active Anti-Neoplastic and Anti-Proliferative Agents |
| WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| US20160220569A1 (en) * | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| BR112017026191B1 (pt) | 2015-06-17 | 2023-10-10 | Pfizer Inc | Compostos tricíclicos inibidores de fosfodiesterase, sua composição farmacêutica e uso dos mesmos |
| CN108348514A (zh) * | 2015-08-28 | 2018-07-31 | 诺华股份有限公司 | 含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用 |
| JP6635374B2 (ja) * | 2015-12-18 | 2020-01-22 | 京都府公立大学法人 | 癌におけるリン酸化ｒｂタンパク質を指標としたイリノテカン感受性予測法 |
| WO2017161253A1 (en) * | 2016-03-18 | 2017-09-21 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| EA202092442A3 (ru) | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| EA201990187A1 (ru) | 2016-07-01 | 2019-07-31 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| CN109789142B (zh) | 2016-07-01 | 2022-08-23 | G1治疗公司 | N-(杂芳基)-吡咯并[3,2-d]嘧啶-2-胺的合成 |
| CA3034875C (en) | 2016-08-23 | 2024-05-28 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| EP3538148A1 (en) | 2016-11-08 | 2019-09-18 | Dana-Farber Cancer Institute | Compositions and methods of modulating anti-tumor immunity |
| MX2019006523A (es) | 2016-12-05 | 2019-10-15 | G1 Therapeutics Inc | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
| TWI823845B (zh) | 2017-01-06 | 2023-12-01 | 美商G1治療公司 | 用於治療癌症的組合療法 |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| CN110325191A (zh) | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
| MX2019010981A (es) | 2017-03-16 | 2020-09-07 | Eisai R&D Man Co Ltd | Terapias de combinacion para el tratamiento de cancer de mama. |
| AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
| EP4455146A3 (en) * | 2017-06-29 | 2025-01-01 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| KR102464677B1 (ko) * | 2017-08-11 | 2022-11-10 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물 |
| WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| US11174252B2 (en) | 2018-02-15 | 2021-11-16 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| CN112218634A (zh) * | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| CA3107750A1 (en) * | 2018-07-27 | 2020-01-30 | California Institute Of Technology | Cdk inhibitors and uses thereof |
| CN120817904A (zh) | 2018-08-24 | 2025-10-21 | 法码科思莫斯有限公司 | 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成 |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| WO2020206035A1 (en) * | 2019-04-01 | 2020-10-08 | G1 Therapeutics, Inc. | Treatment of cdk4/6 inhibitor resistant neoplastic disorders |
| EP3986410A4 (en) * | 2019-06-18 | 2023-06-28 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
| TW202128173A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| EP4652997A3 (en) | 2020-05-19 | 2026-03-04 | Pharmacosmos Holding A/s | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| CN115698015A (zh) | 2020-06-11 | 2023-02-03 | 卢内拉生物技术有限公司 | 选择性cdk4/6抑制剂癌症治疗 |
| TWI906312B (zh) * | 2020-06-15 | 2025-12-01 | 大陸商海南先聲再明醫藥股份有限公司 | 曲拉西利(trilaciclib)之型態形式及製造方法 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| JP2023148228A (ja) * | 2022-03-30 | 2023-10-13 | 東芝ライテック株式会社 | 照明制御装置及び照明制御システム |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| EP4626866A1 (en) * | 2022-11-28 | 2025-10-08 | Assia Chemical Industries Ltd. | Novel trilaciclib intermediates, method of preparation and use thereof |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| CA2335115C (en) | 1998-06-16 | 2009-01-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fused azepinone cyclin dependent kinase inhibitors |
| DE60037394T2 (de) | 1999-01-29 | 2009-01-02 | The Board Of Trustees For The University Of Illinois, Urbana | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE |
| US6958333B1 (en) | 1999-07-26 | 2005-10-25 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
| WO2001044247A2 (en) | 1999-12-16 | 2001-06-21 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| PL359563A1 (pl) | 2000-06-26 | 2004-08-23 | Pfizer Products Inc. | Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne |
| DK1325011T3 (da) | 2000-09-29 | 2004-08-16 | Lilly Co Eli | Fremgangsmåder og forbindelser til behandling af proliferative sygdomme |
| AU2002228692A1 (en) | 2000-12-01 | 2002-06-11 | Bristol-Myers Squibb Pharma Company | 3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors |
| US6667346B2 (en) | 2001-02-28 | 2003-12-23 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones |
| JP2004533449A (ja) | 2001-05-11 | 2004-11-04 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体 |
| DE60303009T2 (de) | 2002-01-22 | 2006-07-13 | Warner-Lambert Co. Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one |
| WO2003093469A2 (en) | 2002-05-01 | 2003-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類 |
| US7482354B2 (en) | 2003-05-22 | 2009-01-27 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| JP4053073B2 (ja) | 2003-07-11 | 2008-02-27 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 選択的ｃｄｋ４阻害剤のイセチオン酸塩 |
| MXPA06004305A (es) | 2003-10-23 | 2006-06-05 | Hoffmann La Roche | Derivados de triaza-espiropiperidina para uso como inhibidores del transformador de glicina 1 en tratamiento de enfermedades neurologicas y neuropsiquiatricas. |
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| WO2005094830A1 (en) | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| US8603763B2 (en) | 2004-04-08 | 2013-12-10 | Cornell Research Foundation, Inc. | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| WO2005117908A2 (en) | 2004-05-28 | 2005-12-15 | Gemin X Biotechnologies, Inc. | Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases |
| ES2411975T3 (es) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas |
| EP1845975A1 (en) | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| NZ564065A (en) | 2005-05-20 | 2011-03-31 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| US7579351B2 (en) | 2005-12-09 | 2009-08-25 | Hoffmann-La Roche Inc. | Tricyclic amide derivatives |
| BRPI0620151A2 (pt) | 2005-12-22 | 2010-06-29 | Wyeth Corp | composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo |
| WO2007124252A2 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| US20070270362A1 (en) | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
| CA2656290A1 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| EP2061469B8 (en) | 2006-09-11 | 2014-02-26 | Curis, Inc. | Quinazoline based egfr inhibitors |
| EP2109450A2 (en) | 2006-12-14 | 2009-10-21 | Panacea Pharmaceuticals, Inc. | Methods of neuroprotection by cyclin-dependent kinase inhibition |
| AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
| WO2009003003A2 (en) | 2007-06-25 | 2008-12-31 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| WO2009085185A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| EP2320903B1 (en) | 2008-07-29 | 2017-01-18 | Nerviano Medical Sciences S.r.l. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| KR101353857B1 (ko) * | 2008-08-22 | 2014-01-21 | 노파르티스 아게 | Ｃｄｋ 억제제로서 피롤로피리미딘 화합물 |
| JP2012504646A (ja) * | 2008-10-01 | 2012-02-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護 |
| CN102231983A (zh) * | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护 |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| CA2761896A1 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| FR2957748B1 (fr) * | 2010-03-16 | 2012-09-07 | St Microelectronics Grenoble 2 | Composant electronique a montage en surface |
| CN102299073A (zh) | 2010-06-25 | 2011-12-28 | 无锡华润上华半导体有限公司 | Vdmos器件及其制作方法 |
| MX379532B (es) * | 2010-10-25 | 2025-03-10 | G1 Therapeutics Inc | Inhibidores de cdk. |
| US8691830B2 (en) * | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| AU2011323455B2 (en) | 2010-11-02 | 2017-07-27 | Promega Corporation | Coelenterazine derivatives and methods of using same |
| WO2012068381A2 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6 |
| HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| MY161237A (en) | 2011-07-01 | 2017-04-14 | Novartis Ag | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer |
| EP2736895B1 (en) | 2011-07-27 | 2016-01-06 | Astrazeneca AB | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| WO2013148748A1 (en) | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
| MY175254A (en) | 2012-04-26 | 2020-06-17 | G1 Therapeutics Inc | Synthesis of lactams |
| AU2013296237B2 (en) | 2012-08-03 | 2019-05-16 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
| US9241941B2 (en) | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
| KR20150089053A (ko) | 2012-11-28 | 2015-08-04 | 노파르티스 아게 | 조합 요법 |
| US20140271460A1 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly Active Anti-Neoplastic and Anti-Proliferative Agents |
| US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| US9527857B2 (en) * | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| WO2014168975A1 (en) | 2013-04-08 | 2014-10-16 | Pharmacyclics, Inc. | Ibrutinib combination therapy |
| SG10201709926VA (en) | 2013-05-30 | 2017-12-28 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
| WO2015084892A1 (en) | 2013-12-02 | 2015-06-11 | Cornell University | Methods for treating b cell proliferative disorders |
| CN105916848B (zh) | 2013-12-31 | 2018-01-09 | 山东轩竹医药科技有限公司 | 激酶抑制剂及其用途 |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| US9374037B2 (en) | 2014-10-30 | 2016-06-21 | M/A-Com Technology Solutions Holdings, Inc. | Voltage-controlled oscillator with mask-selectable performance |
| US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CN109789142B (zh) * | 2016-07-01 | 2022-08-23 | G1治疗公司 | N-(杂芳基)-吡咯并[3,2-d]嘧啶-2-胺的合成 |
| MX2019006523A (es) * | 2016-12-05 | 2019-10-15 | G1 Therapeutics Inc | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
| CA3045037A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| TWI823845B (zh) * | 2017-01-06 | 2023-12-01 | 美商G1治療公司 | 用於治療癌症的組合療法 |
| US11395821B2 (en) * | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| WO2018148576A1 (en) * | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| CN110325191A (zh) * | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
| EP4455146A3 (en) * | 2017-06-29 | 2025-01-01 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| WO2019136244A1 (en) | 2018-01-04 | 2019-07-11 | G1 Therapeutics, Inc. | Heterocyclic compounds for the treatment of abnormal cellular proliferation |
| WO2019136451A1 (en) * | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| CN112218634A (zh) * | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| WO2020023502A1 (en) * | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3986410A4 (en) * | 2019-06-18 | 2023-06-28 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
| TW202128173A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
-
2014
- 2014-03-14 US US14/214,048 patent/US9527857B2/en active Active
- 2014-03-14 HU HUE14762438A patent/HUE046653T2/hu unknown
- 2014-03-14 CN CN201810443050.5A patent/CN108434149B/zh active Active
- 2014-03-14 ES ES14762438T patent/ES2761406T3/es active Active
- 2014-03-14 EP EP14762438.1A patent/EP2968290B1/en active Active
- 2014-03-14 CA CA2906166A patent/CA2906166C/en active Active
- 2014-03-14 JP JP2016503092A patent/JP6337083B2/ja active Active
- 2014-03-14 US US14/212,430 patent/US9487530B2/en active Active
- 2014-03-14 PT PT147624381T patent/PT2968290T/pt unknown
- 2014-03-14 ES ES14765105T patent/ES3032492T3/es active Active
- 2014-03-14 CA CA2906156A patent/CA2906156C/en active Active
- 2014-03-14 CN CN201480027269.7A patent/CN105407889B/zh active Active
- 2014-03-14 HR HRP20192168TT patent/HRP20192168T1/hr unknown
- 2014-03-14 US US14/212,911 patent/US9464092B2/en active Active
- 2014-03-14 LT LT14762438T patent/LT2968290T/lt unknown
- 2014-03-14 WO PCT/US2014/029429 patent/WO2014144847A2/en not_active Ceased
- 2014-03-14 EP EP14765105.3A patent/EP2968291B1/en active Active
- 2014-03-14 SI SI201431380T patent/SI2968290T1/sl unknown
- 2014-03-14 SM SM20190681T patent/SMT201900681T1/it unknown
- 2014-03-14 JP JP2016502870A patent/JP6430483B2/ja active Active
- 2014-03-14 DK DK14762438T patent/DK2968290T3/da active
- 2014-03-14 CN CN201480027281.8A patent/CN105473140B/zh active Active
- 2014-03-14 ME MEP-2019-338A patent/ME03557B/me unknown
- 2014-03-14 EP EP19198057.2A patent/EP3653209A1/en active Pending
- 2014-03-14 EP EP25170501.8A patent/EP4596051A3/en active Pending
- 2014-03-14 CN CN201810253672.1A patent/CN108283644B/zh active Active
- 2014-03-14 PL PL14762438T patent/PL2968290T3/pl unknown
- 2014-03-14 RS RS20191537A patent/RS59790B1/sr unknown
- 2014-03-14 WO PCT/US2014/028685 patent/WO2014144326A1/en not_active Ceased
-
2016
- 2016-10-07 US US15/288,878 patent/US9931345B2/en active Active
- 2016-11-03 US US15/342,990 patent/US10085992B2/en active Active
- 2016-12-21 US US15/387,083 patent/US10076523B2/en active Active
-
2018
- 2018-04-02 US US15/943,278 patent/US10660896B2/en active Active
- 2018-05-07 JP JP2018089382A patent/JP6517401B2/ja active Active
- 2018-08-24 US US16/112,360 patent/US10966984B2/en active Active
- 2018-08-24 US US16/112,362 patent/US10434104B2/en active Active
- 2018-10-30 JP JP2018204234A patent/JP6767456B2/ja active Active
- 2018-11-01 US US16/178,419 patent/US10925878B2/en active Active
-
2019
- 2019-04-16 JP JP2019077828A patent/JP6738933B6/ja active Active
- 2019-12-11 CY CY20191101306T patent/CY1122434T1/el unknown
-
2020
- 2020-05-28 US US16/886,309 patent/US11040042B2/en active Active
- 2020-07-17 JP JP2020123189A patent/JP7250737B2/ja active Active
- 2020-09-16 JP JP2020155691A patent/JP7213854B2/ja active Active
-
2021
- 2021-02-22 US US17/181,638 patent/US11654148B2/en active Active
- 2021-04-05 US US17/222,873 patent/US11717523B2/en active Active
-
2023
- 2023-01-17 JP JP2023005413A patent/JP2023052449A/ja not_active Ceased
- 2023-03-06 US US18/117,983 patent/US20230364098A1/en active Pending
- 2023-03-20 JP JP2023044746A patent/JP2023078341A/ja not_active Withdrawn
- 2023-08-07 US US18/231,091 patent/US20230381189A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2761406T3 (es) | Protección transitoria de células normales durante una quimioterapia | |
| HK40031250A (en) | Transient protection of normal cells during chemotherapy | |
| HK1258477B (en) | Transient protection of normal cells during chemotherapy | |
| HK1223293B (en) | Transient protection of normal cells during chemotherapy |